Pulmatrix (PULM) EBT Margin (2014 - 2024)
Pulmatrix (PULM) posted EBT Margin of 62633.33% for Q4 2024, down 8785.19% sequentially from 704.92% in Q3 2024, and down 6253719.0% YoY from N/an in Q1 2024.
Pulmatrix (PULM) EBT Margin (2014 - 2024) Analysis & Trends
Pulmatrix has reported EBT Margin for 11 years, with the latest figure at 62633.33% in Q4 2024.
- Quarterly EBT Margin fell 6253719.0% year-over-year to 62633.33% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 307.9% (down 5860.0% YoY) and the FY2024 annual result came in at 127.81%, up 41023.0% from the prior year.
- EBT Margin slipped to 62633.33% in Q4 2024 per PULM's latest filing, from 704.92% in the prior quarter.
- Over five years, EBT Margin peaked at 74.29% in Q3 2020 and troughed at 62633.33% in Q4 2024.
- A 5-year average of 3456.2% and a median of 305.32% in 2021 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2024: EBT Margin soared 67346 bps in 2022, then tumbled 6253719 bps in 2024.
- Over 5 years, EBT Margin stood at 136.5% in 2020, then slumped by 597 bps to 951.97% in 2021, then surged by 71 bps to 278.51% in 2022, then jumped by 65 bps to 96.14% in 2023, then sank by 65048 bps to 62633.33% in 2024.
- According to Business Quant data, EBT Margin over the past three periods registered 62633.33%, 704.92%, and 392.4% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -62,633.33% |
| Sep 30, 2024 | -704.92% |
| Jun 30, 2024 | -392.40% |
| Mar 31, 2024 | -229.16% |
| Dec 31, 2023 | -96.14% |
| Sep 30, 2023 | -378.67% |
| Jun 30, 2023 | -239.86% |
| Mar 31, 2023 | -334.62% |
| Dec 31, 2022 | -278.51% |
| Sep 30, 2022 | -295.46% |
| Jun 30, 2022 | -365.66% |
| Mar 31, 2022 | -454.40% |
| Dec 31, 2021 | -951.97% |
| Sep 30, 2021 | -794.01% |
| Jun 30, 2021 | -183.94% |
| Mar 31, 2021 | -315.18% |
| Dec 31, 2020 | -136.50% |
| Sep 30, 2020 | -74.29% |
| Jun 30, 2020 | -94.83% |
| Mar 31, 2020 | -170.09% |